Therapeutic compounds and methods of use

Details Therapeutic compounds and methods of use Therapeutic compounds and methods of use

2011-01-04

2011-01-04

Wilson, James O (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

C558S415000, C558S423000, C514S463000, C514S520000, C514S519000, C514S522000

Reexamination Certificate

active

07863327

ABSTRACT:
Compounds and methods useful for chemopreventative treatment of diseases such as cancer, Alzheimer's disease, Parkinson's disease, inflammatory bowel diseases, and multiple sclerosis.

REFERENCES:
patent: 4395423 (1983-07-01), Neumann
patent: 4808614 (1989-02-01), Hertel
patent: 5013649 (1991-05-01), Wang et al.
patent: 5064823 (1991-11-01), Lee et al.
patent: 5401838 (1995-03-01), Chou
patent: 5426183 (1995-06-01), Kjell
patent: 5464826 (1995-11-01), Grindey et al.
patent: 5521294 (1996-05-01), Wildfeuer
patent: 5597124 (1997-01-01), Kessel et al.
patent: 5603958 (1997-02-01), Morein et al.
patent: 5606048 (1997-02-01), Chou et al.
patent: 5972703 (1999-10-01), Long et al.
patent: 6025395 (2000-02-01), Breitner et al.
patent: 6303569 (2001-10-01), Greenwald et al.
patent: 6326507 (2001-12-01), Gribble et al.
patent: 6485756 (2002-11-01), Aust et al.
patent: 6974801 (2005-12-01), Honda et al.
patent: 7176237 (2007-02-01), Honda et al.
patent: 7265096 (2007-09-01), Gallop et al.
patent: 7288568 (2007-10-01), Gribble et al.
patent: 7435755 (2008-10-01), Konopleva et al.
patent: 2002/0042535 (2002-04-01), Gribble et al.
patent: 2005/0276836 (2005-12-01), Wilson et al.
patent: 2005/0288363 (2005-12-01), Gribble et al.
patent: 2007/0155742 (2007-07-01), Honda et al.
patent: 2008/0220057 (2008-09-01), Gribble et al.
patent: 2009/0093447 (2009-04-01), Konopleva et al.
patent: 10 2005 041613 (2007-03-01), None
patent: 0 272 891 (1988-06-01), None
patent: 0 329 348 (1995-07-01), None
patent: 0 376 518 (1995-11-01), None
patent: 0 576 230 (1996-04-01), None
patent: 0 577 303 (1997-10-01), None
patent: 0 712 860 (2001-12-01), None
patent: WO 91/15498 (1991-10-01), None
patent: WO 98/00173 (1998-01-01), None
patent: WO 98/32762 (1998-07-01), None
patent: WO 99/33483 (1999-07-01), None
patent: WO 99/65478 (1999-12-01), None
patent: WO 00/73253 (2000-12-01), None
patent: WO 01/01135 (2001-01-01), None
patent: WO 02/03996 (2002-01-01), None
patent: WO 02/47611 (2002-06-01), None
patent: WO 03/043631 (2003-05-01), None
patent: WO 03/059339 (2003-07-01), None
patent: WO 2005/042002 (2005-05-01), None
patent: WO 2005/046732 (2005-05-01), None
patent: WO 2006/029221 (2006-03-01), None
patent: WO 2007/005879 (2007-01-01), None
patent: WO 2007/069895 (2007-06-01), None
patent: WO 2008/111497 (2008-09-01), None
patent: WO 2008/136838 (2008-11-01), None
patent: WO 2009/023232 (2009-02-01), None
Bollag and Holdener, “Retinoids in cancer prevention and therapy,”Annals of Oncology, 3:513-526, 1992.
Dragnev et al., “The retinoids and cancer prevention mechanisms,”The Oncologist, 5:361-368, 2000.
Agarwal and Mehta, “Possible involvement of Bcl-2 pathway in retinoid X receptor alpha-induced apoptosis of HL-60 cells,”Biochem Biophys Res Commun, 230(2):251-253, 1997.
Al-alami et al., “Divergent effect of taxol on proliferation, apoptosis and nitric oxide production in MHH225 CD34 positive and U937 CD34 negative human leukemia cells,”Leukemia Res., 22:939-945, 1998.
Ambs et al., “p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells,”Nat. Med., 4(12):1371-1376, 1998.
Andreeff et al., “Expression of bcl-2-related genes in normal and AML progenitors: Changes induced by chemotherapy and cationic acid,”Leukemia, 13:1881-1892, 1999.
Andreeff et al., “PPARgamma nuclear receptor as a novel molecular target in leukemias,”2002 Keystone Symposia ,Abstract No. 501, 2002.
Andreeff, “Acute myeloid leukemia,”In: Cancer Treatment, Haskell (Ed.), W. B. Saunders, 911-922, 1995.
Beran et al., “Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia,”J. Clinical Oncology, 17(9):2819-2830, 1999.
Bliard et al., “Glycosylation of acids under phase transfer conditions. Partial synthesis of saponins,”Tetrahedron Lett., 35:6107-6108, 1994.
Bogdon and Ding, “Taxol, a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor α and interleukin-1 in macrophages,”J. Leukoc. Biol., 52(1):119-121, 1992.
Boolbol et al., “Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis,”Cancer Res., 56(I1):2556-2560, 1996.
Brookes et al., “The triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid and its derivatives elicit human lymphoid cell apoptosis through a novel pathway involving the unregulated mitochondrial permeability transition pore,”Cancer Res., 67:1793-1802, 2007.
Carter et al., “Expression of survivin, a member of the inhibitor of apoptosis (IAP) family of caspase inhibitors is expressed in AML and regulated by cytokines and ATRA,”Blood, 94(Suppl 1):479a, Abstract # 2142, 1999.
Castaigne et al., “All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia,”Blood, 76(9):1704-1709, 1990.
Chauhan et al., “The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance,”Blood, 103:3158-3166, 2004.
Chintharlapalli et al., “2-Cyano-3,12-dioxoolean-1,9-dien-28-oic acid and related compounds inhibit growth of colon cancer cells through peroxisome proliferator-activated receptor gamma-dependent and -independent pathways,”Mol. Pharmacol., 68:119-128, 2005.
Dezulbe et al., “Interim results of a phase I trial with a novel orally administered synthetic triterpenoid RTA 402 (CDDO-Me) in patients with solid tumors and lymphoid malignancies,”J. Clin. Oncol., 2007 ASCO Annual Meeting Proceedings, 25(18S):14101, 2007.
Drach et al., “Induction of differentiation in myeloid leukemia cell lines and acute promyelocytic leukemia cells by liposomal all-trans-retinoic acid,”Cancer Research, 53:2100-2104, 1993.
Drefahl and Huneck, “Nor-olea-12-enol-17-amin und Olea-12-enol-28-amin,”Chem. Ber., 91:278-281, 1958.
DuBois et al., “Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors,”Gastroenterology, 110:1259-1262, 1996.
Elliot et al., “The triterpenoid CDDO inhibits expression of matrix metalloproteinase-1, matrix metalloproteinase-13 and Bcl-3 in primary human chondrocytes,”Arthritis Res. Ther., 5:R285-R291, 2003.
Elsawa et al., “Preferential Inhibition of Malignant Cell Growth by CDDO in Waldenstrom Macroglobulinemia,”Blood, 108(11):2528, 2006.
Elstner et al., “Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice,”Proc. Natl. Acad. Sci. USA, 95:8806-8811, 1998.
Engel et al., “Quantitation of minimal residual disease in acute myelogenous leukemia and myelodysplastic syndromes in complete remission by molecular cytogenetics of progenitor cells,”Leukemia, 13:568-577, 1999.
Estey et al., “Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia,”Blood, 94:2230-2235, 1999.
Estey et al., “Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin + all-trans retinoic acid + granulocyte-colony stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrom,”Blood, 93(8):2478-2484, 1999.
Gura et al., “Systems for identifying new drugs are often faulty,”Science, 278:1041-1042, 1997.
Hail et al., “Evidence supporting a role for calcium in apoptosis induction by the synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO),”J. Biol. Chem., 279:11179-11187, 2004.
Huang et al., “Inhibition of skin tumorigenesis by Rosemary and its constituents carnosol and ursolic acid,”Cancer Res., 54:701-708, 1994.
Hyer et al., “Syntheti

Affiliated with

Also associated with

Rating

Therapeutic compounds and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic compounds and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic compounds and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2732427